
11 Jan 2019 Research
Myelofibrosis: Finding new ways to treat patients
Myelofibrosis is a fatal bone marrow cancer. The disease is caused by excessive secretion of factors by cancerous platelet-producing cells called megakaryocytes. These secretions cause the replacement of normal bone marrow tissue with fibrous scar tissue.
Dr Chen’s team can successfully recreate this pathological bone marrow environment in the laboratory, and their preliminary research data shows that reduced levels of a protein complex called FANCcore leads to more myelofibrosis.
Dr Chen’s team hypothesise that loss of the protein complex FANCcore increases the growth of myelfibrosis by altering megakaryocytes. Dr Chen uses both human tissue cultures and mouse models to examine the cellular and molecular changes to megakaryocytes following the absence of the FANCcore complex and to understand how these changes cause myelofibrosis.
The team hopes that by focusing on the role of FANCcore in megakaryocyte biology, they can reveal new ways to treat myelofibrosis.
Related posts
11 February 2022
International Childhood Cancer Day: Dr Samanta Mariani reflects on her research into infant leukaemia
On International Childhood Cancer Day, Dr Samanta Mariani reflects on her research into infant leukaemia, what drives her in her work and her hopes for the future.
17 April 2024
“Every little thing is gonna be alright” – three little birds tattoo marks mum’s recovery from one of the least survivable cancers
New research by Leukaemia UK which could reduce the side-effects of treatment for acute myeloid leukaemia (AML) welcomed by family affected by the disease. A family who was devastated when…
4 June 2022
Leukaemia UK is looking for volunteers for their Patient Experience Advisory Panel
Leukaemia UK is committed to championing advancements in better treatments and care for all. We want to ensure the needs of patients are at the heart of everything we do, and that the voices of people affected by leukaemia and related conditions are being heard. That is why we are setting up a Patient Experience Advisory Panel.
21 May 2020
A new clinical trial announced
A study into the impact of severe covid-19 infection on patients who receive stem cell transplants for blood cancers and blood disorders.